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Long-acting neuroleptics have become the mainstay of
the long-term treatment of schizophrenia, improving
compliance and thus preventing relapse. Since
schizophrenia is a common condition and treatment is
usually long-term, this has important financial implications.
Objective. Generic substitution is an important cost-
saving measure and generic psychopharmacological
agents are also currently available in South Africa. There
have been concerns about the quality of these products,
but these often arise from anecdotal reports. This study
was undertaken to compare the clinical efficacy of a
_ generic substitute of fluphenazine decanoate with the
original product.
Design and setting. The study was a double-blind
randomised trial involving two parallel groups - generic
substitution v. original product. Chronic schizophrenics,
aged between 18 and 65 years, who had been on a
constant dose of fluphenazine decanoate for at least 3
months preceding the trial, all treated as outpatients in the
community, were studied.
The Positive and Negative Syndrome Scale (PANSS)
(positive scale) was used as measuring scale and patients
were evaluated at inclusion and then every 2 weeks for the
next 12 weeks.
Results. Both groups had a median change of zero in
PANSS scores over the 12-week period. No clinically
significant differences between the change in PANSS
score were found in respect of the two products.
Conclusions. Generic substitution could play an
important role in containing the costs of health care in
Departments of Psychiatry and Biostatistics, University of the
Orange Free State, Bloemfontein
G C Verster, MB ChB, Fe Psych (SA), MMed (Psych)
G Jouber1. BA, MSc
Oranje Hospital, Bloemfontein
M Stevens, B Pharm
Free State Psychiatric Community Services, Welkom
H van der Merwe, o.p Gen N= & Psych
~ Volume 88 No. 3 March 1998 SAMJ
South Africa. Concerns about the quality and efficacy of
these drugs should be investigated. In this study, no
significant differences in the efficacy of the two products
were found.
S Atr Med J 1998; 88: 260-262.
The maintenance treatment of chronic schizophrenics with
long-acting neuroleptics remains an integral part of the
management of this condition, especially in rural areas and
in cases where compliance is a problem. The prevention of
relapse by these products has been proved in a number of
trials, These patients also have a more rapid recovery rate
than patients prescribed oral neuroleptics in cases of
exacerbation.'
Fluphenazine decanoate is a widely used long-acting
neuroleptic and has proved to be at least as effective as
other available products.' The generic pharmaceutical
industry has expanded rapidly during the last 2 decades!
The need to contain the spiralling costs of health care has
largely been responsible for this. Generic prescribing is
perceived as providing cost-effective alternatives where and
when available.3-5 Unfortunately, doubts have been
expressed about the quality control of these products.5-'
There are currently numerous generic
psychopharmacological agents available in South Africa,
among them two generic substitutes for fluphenazine
decanoate.' These products are both cheaper than the
innovator product.
Substitution of a generic drug product for an innovator
product requires that the products be not only
pharmaceutically equivalent, but also bio-equivalent. This
implies that any difference in the rate and extent of
absorption must be judged to be clinically insignificant.
Much more attention has been given to the development of
requirements for immediate-release oral products than of
controlled-release products.'
Bio-equivalence testing is intended to establish that the
rate and extent of absorption are similar and that there are
therefore not likely to be any differences in safety and
efficacy between a generic and an innovator product, Le.
that there is therapeutic equivalence. While it seems
reasonable to assume that if products are bio-equivalent
based on pharmacokinetic measurements, they will also be
therapeutically equivalent, the validity of this assumption has
not been examined systematically. In the past there was also
no universally accepted standard for requirements and
guidelines for bio-equivalence testing. This implied that data
indicative of bio-equivalence in one country did not
necessarily support such a conclusion in another country!
This is changing and there are international attempts to
standardise procedures and regulations.
The Medicines Control Council (MCC) is responsible for
regulating the availability of generic products in South Africa.
Guidelines on the data required as evidence of efficacy are
provided (MCC Circular 14/95) and also pertain to generic
products. Data submitted must be comparative and, in the
case of a generic, the product must be compared with a
well-established innovator product (reference product), the
choice of which must be justified by the applicant. In the
case of a product like fluphenazine decanoate, proof of
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Table 11. Demographic characteristics of patients
Thirty patients were initially included in the trial, but only 27
completed the trial. One patient withdrew consent and 2
were lost to follow-up.
The median age of the group receiving the original
product was 48 years and that of the group receiving the
generic product was 44 years. The minimum and maximum
ages in the respective groups were also similar, and there
was a preponderance of male patients in both groups
(Table 11).
efficacy is required. This is assessed on the basis of bio-
availability or any other method an applicant wishes to
submit, provided the rationale for the particular method is
included. Proof of clinical efficacy is not required.
The generic fluphenazine decanoate has been used locally
and there have been anecdotal reports by nursing personnel
of inferior therapeutic efficacy. The use of the generic
product is relevant, since it costs less than the original, and
doubts about its efficacy should be addressed. It was
therefore decided to compare the efficacy of the generic
product with that of the original in a randomised trial.
The Positive and Negative Syndrome Scale (PANSS) for
schizophrenia is a valid instrument for rating symptoms in
this condition.g-" It has high inter-rater reliability and
describes symptoms well. '° It is based on two established
psychiatric rating systems and was conceived as an
operationalised, drug-sensitive instrument that provides
balanced representation of positive and negative symptoms.
It constitutes four scales measuring positive and negative





















A number of r::omplaints were noted during the various
visits (Table V), but since these applied only to the visit in
question they were not statistically analysed. The authors'
clinical global impression was that the side-effect profile of
the two products did not differ notably.
The median PANSS score in both groups was the same at
visit 1 (Table Ill) and remained unchanged throughout the 12
weeks of the trial (see Table IV). The 95% confidence
intervals for the median difference between group 1 and
group 2 in respect of the changes were all 0 - 1, indicating
that there is either no difference between the two groups or
that, contrary to expectation, group 1 would increase by at
most 1 point more than group 2 on the PANSS positive
scale. Since the maximum score is 49, a difference of 1
point is not considered clinically significant.
Table IV. Changes in PANSS scores
Visit
1 to 2 1 to 3 1 to 4 1 to 5 1 to 6 1 to 7
Group 1 (original product)
Minimum -3 -3 -3 -3 -3 -3
Median 0 0 0 0 0 0
Maximum 1 4 1 2 1 2
Group 2 (generic product)
Minimum --£ --£ -10 -10 -10 -10
Median 0 0 0 0 0 0
Maximum 0 1 0 1 0 0














Thirty patients with schizophrenia aged between 18 and 65
years, who were treated with fluphenazine decanoate in the
community and from whom informed consent had been
obtained, were included in the trial. To be eligible for the
trial, the patients had to have been on unchanged dosages
of fluphenazine for at least 3 months before the trial.
Patients who were receiving other antipsychotics in addition
to fluphenazine were not included.
This was a double-blind study with patients randomised
to two parallel groups - one group receiving the original
product (group 1) and the other the generic substitute (group
2), with dosages unchanged during the preceding 3 months.
The medication was supplied to the main investigator in
syringes marked only by the patient's identification number
and by the dosage of fluphenazine. The two products were
indistinguishable in respect of colour and consistency.
The positive scale of the PANSS was used as rating scale
and was completed by the same investigator for each
patient at admission and every 2 weeks thereafter for 12
weeks. This scale consists of seven positive symptom items
(Table I) and each item is rated from 1 to 7, according to the
absence or degree of presence of the symptom. A maximum
score of 49 and a minimum score of 7 could therefore be
obtained at each visit. Changes in PANSS scores from
baseline to each visit were calculated, and 95% confidence
intervals were calculated for the median difference of these
changes between groups 1 and 2. Complaints and side-
effects were also noted at each visit.
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An assessment of
asthmatic patients at four
Western Cape community
pharmacies
Objectives. To identify the profile of asthmatic patients
visiting community pharmacies and to assess the
appropriateness of their current asthma therapy.
Design. Patients were identified as either chronic, newly
diagnosed or undiagnosed. Asthma status was assessed
from their current symptom and medication profiles and
from performance in an airways responsiveness test.
Reversibility of > 15% was suggestive of probable airflow
obstruction and such patients were referred to a medical
practitioner.
Setting. Four community pharmacies located in different
socio-economic areas, viz. Khayelitsha, Wynberg,
Mitchell's Plain and Vrijzee, were selected.
Subjects. Participants over the age of 6 years, who
suffered from recurrent cough, wheeze, chest tightness
and/or breathlessness and used over-the-counter (OTC)
and/or asthma medications, completed a questionnaire
and participated in the airways responsiveness test.
Outcome measures. Effective control of asthma based
on minimal symptoms, appropriate use of bronchodilator
and anti-inflammatory therapies and absence of airflow
obstruction.
Results. Of the 220 participants, 120 were identified as
chronic, 7 as newly diagnosed and 93 as undiagnosed.
Chronic asthmatics suffered daily symptoms and used
inadequate prophylactic anti-inflammatory therapy. Many
undiagnosed asthmatics were unaware of their symptoms
and took OTC medication indiscriminately. Based on peak
expiratory flow rate measurements, > 50% of the screened
patients displayed a reversibility of > 15%.
Conclusions. Chronic and many undiagnosed asthmatic
patients frequent community pharmacies for their
medication. Such patients suffer recurrent asthma
symptoms and use medication inappropriately, which
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On the basis of this study it would seem that there are no
significant differences in the clinical efficacy of the two
products studied. The low PANSS (positive scale) scores
indicated that patients were stable at inclusion and remained
stable throughout the trial. It has to be kept in mind that the
duration of the study was only 12 weeks and, when
evaluating relapse in schizophrenia, studies of longer
duration would have even more predictive value.
Nevertheless, this study could be used to allay concerns
that the generic product is inferior to the original product. It
would also appear as if there is no difference in the side-
effect profile of the two products.
Recruitment of patients for the study was reasonably easy
once the rationale and the absence of placebo control were
explained to the patients. The simple design and minimal
financial expenditure suggest that similar studies could
easily be undertaken and could aid in answering queries
about the efficacy of a number of generic products.
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